Nearly Half of COPD Patients Receive More Than One COPD Medication

Quarterly Treatment Algorithm Analysis for Chronic Obstructive Pulmonary Disease Now Available from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that about half (49.3 percent) of recently treated chronic obstructive pulmonary disease (COPD) patients receive more than one COPD therapy. According to Treatment Algorithms in Chronic Obstructive Pulmonary Disease, market share leaders GlaxoSmithKline’s long-acting beta2 agonist/inhaled corticosteroid (LABA/ICS) Advair and Boehringer Ingelheim/Pfizer’s long-acting muscarinic antagonist (LAMA) Spiriva are the most common COPD drugs to be added to recently treated patients’ therapies.

Historical analysis of U.S. patient-level claims data also reveals that a moderate percentage of newly diagnosed patients receive combination therapy as they progress through lines of treatment. The most common combinations prescribed in newly diagnosed patients moving from the first to the second line are albuterol plus Advair, Spiriva or AstraZeneca’s Symbicort and Spiriva plus Advair.

“Because COPD is a progressive disease and there is a lack of disease modifying therapies, nearly all COPD patients will eventually require multiple drugs to control their symptoms,” said Decision Resources Therapeutic Area Director Madhuri Borde, Ph.D. “Our analysis demonstrates that it is common for physicians to maintain COPD patients on multiple products with different mechanisms of action. For marketers of COPD drugs, understanding the add-versus-switch treatment patterns and dynamics is important to maximizing a drug’s sales potential.”

The analysis is part of Decision Resources’ Treatment Algorithms series. Through examination of patient-level claims data, the Treatment Algorithms series provides exceptional insight into physicians’ prescribing trends and the factors that drive therapy choice, from diagnosis through multiple courses of treatment, for a specific disease. The Treatment Algorithms series is updated quarterly.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources
Lisa Osgood, 781-993-2606
[email protected]
or
Decision Resources Group
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Cardiology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Merck & Co. set out to answer the question of whether lung cancer patients with KRAS mutations respond as well to Keytruda as others do.

Merck and Roche are no strangers to sparring with their I-O meds Keytruda and Tecentriq, but in TNBC, Keytruda's latest data take the prize.

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.